Paving a pathway for drug development in HER2-positive biliary tract cancer
Christopher T Chen1, Lipika Goyal2
1Department of Medicine, Stanford University School of Medicine, Palo Alto, CA, USA.
The Lancet. Oncology
|September 3, 2021
Abstract
No abstract available in PubMed .
More Related Videos
13:19Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery
Published on: April 26, 2024
3.1K
09:29Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
Published on: September 30, 2016
14.0K
